McKinsey January 28, 2025
From the shop floor to the supply chain, gen AI can transform how biopharma companies operate. Four use cases show how it can enhance productivity, improve quality, and reduce costs.
Gen AI has become a hot topic among leaders at most big companies, more than two-thirds of which intend to increase their investments in the technology over the next three years. McKinsey has estimated the opportunity for gen AI in biopharmaceutical operations at $4 billion to $7 billion annually through workload and cost reductions, productivity gains, improvements to equipment effectiveness, and quality enhancements. Many biopharma organizations now have sophisticated operations and are moving to use gen AI to take advantage of their data repositories. However, only a few organizations have...
Today's Sponsors
Today's Sponsor